Health Care · Services-Medical Laboratories

FLGT Fulgent Genetics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1674930109 filings
Russell 2000

FLGT at a glance

Fulgent Genetics, Inc. (FLGT, SEC CIK 1674930) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 28, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Fulgent Genetics, Inc. (FLGT) reported revenue of $322.7 million (up 13.8% from FY2024) and a net loss of $60.5 million.
  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Fulgent Genetics, Inc. (FLGT) shares worth $186.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Xie Jian on September 2, 2026 of 2,127 shares at $19.66 per share.
  • In the last 90 days, FLGT insiders reported 0 open-market purchases ($0) and 4 open-market sales ($117K) on Form 4, a net sale of $117K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$322.7M
+13.8% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$117K
13F holders
24 funds
$186.9M · −1 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 1.01 · Item 2.03

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material risk-factor changes from 2025 10-K, including no newly added quarterly risk
  • Billing-system transition: processing backlogs and collection delays may reduce collections, gross margin, liquidity, and results
  • Legal investigations and audits: unfavorable outcomes remain uncertain, with potential defense costs, settlements, management diversion, and reputational harm
  • Largest-customer concentration: customer insourcing continues reducing precision-diagnostics revenue during 2026
  • Liquidity dependence: $112.3 million IRS refund drove operating cash flow, while excluding it operations used approximately $19.8 million

Management Discussion & Analysis

  • Revenue $90.4M, up $6.3M, or 8% YoY
  • Gross margin 35% vs 42% YoY, operating loss $22.5M vs $15.4M
  • Best segment anatomic pathology: revenue $40.9M, up $14.9M YoY
  • Worst segment precision diagnostics: revenue $41.8M, down $8.9M YoY
  • Cash resources $652.4M, operating cash flow $92.6M, including $112.3M tax refund; stock repurchases $64.1M YTD
  • Outlook: largest-customer revenue decline, billing-transition collection delays, rising clinical-trial spending and gross-margin uncertainty

AI summary of the FLGT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • 44,644-square-foot Needham facility supporting office, R&D, diagnostics, light manufacturing and warehousing
  • Initial rent $132,071.83 monthly, with 3.0% annual escalators

Item 2.03: Creation of a Direct Financial Obligation

  • Direct financial obligation details incorporated from Item 1.01, indicating a related material agreement
  • Investors should review Item 1.01 for borrowing amount, repayment terms, interest rate and purpose
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced by Fulgent Genetics
  • Press release furnished as Exhibit 99.1, containing the company’s financial results and management disclosures

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation released November 5, 2026
  • Presentation provides business updates and summaries for investors

Item EX-99.1: Item EX-99.1

  • Q3 revenue $90.4M, up approximately 8% year over year, but GAAP gross margin fell to 35.3% from 42.2%
  • GAAP loss widened to $13.2M, or $0.48 per share, from $6.6M, reflecting continued operating pressure

Item EX-99.2: Item EX-99.2

  • Investor presentation dated November 5, 2026 highlights diagnostics scale, oncology pipeline, and balance-sheet flexibility
  • Q3 2026 revenue $90M, up 8% year over year, with LTM operating cash flow of $14M
Filed Jul 30, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for quarter ended June 30, 2026
  • Press release issued July 30, 2026

Item 7.01: Regulation FD Disclosure

  • Updated investor presentation released July 30, 2026, providing refreshed business information for the investment community
  • Presentation available through Fulgent Genetics’ investor-relations website and furnished as Exhibit 99.2

Item EX-99.1: Item EX-99.1

  • Q2 revenue $85.4M, up 20.1% sequentially, but GAAP gross margin fell to 30.1% from 42.1% year over year
  • GAAP loss widened to $29.5M, or $1.05 per share, versus $19.0M, or $0.62, in Q2 2025

Item EX-99.2: Item EX-99.2

  • Q2 2026 revenue $85M, up 4% year over year, indicating modest growth across laboratory services and diagnostics
  • LTM operating cash flow $(84)M, with $106M federal tax refund delayed, creating near-term liquidity sensitivity

AI summaries of FLGT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FLGT

Don't miss the next FLGT filing

  • Alerts as it files. A push when FLGT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FLGT, by share count.
  • Ask anything. An AI agent that reads every FLGT filing and answers with sources.

FLGT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gao HanlinFOct 26, 2026$20.22
Kim PaulFOct 26, 2026$20.22
Xie JianFOct 26, 2026$20.22
Xie JianSellSep 2, 2026$19.66
Gao HanlinSellSep 2, 2026$19.66
Hsieh MingFSep 1, 2026$19.59
Kim PaulFSep 1, 2026$19.59
Xie JianSellAug 27, 2026$19.91

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$283.5M$322.7M
Gross Profit$104.5M$107.2M$130.9M
Operating Income-$195.5M-$73.9M-$91.1M
Net Income-$167.8M-$42.7M-$60.5M
Gross Margin-37.8%40.6%
Op. Margin--26.1%-28.2%
Net Margin--15.1%-18.8%
Balance Sheet
Total Assets$1.2B$1.2B$1.2B
Equity-$1.1B$1.1B
ROE--3.8%-5.4%
Cash Flow
Operating CF-$21.1M-$101.6M
CapEx-$40.3M$22.6M

Source: XBRL data in Fulgent Genetics, Inc. (FLGT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FLGT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FLGT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$186.9M
Q2 202625$167.5M
Q1 202627$135.9M
Q4 202524$260.8M
Q3 202523$239.1M
Q2 202524$182.3M
Q1 202523$133.2M
Q4 202421$144.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 191 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FLGT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 28, 2026--
4Oct 28, 2026--
4Oct 28, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
4Aug 28, 2026--
8-KJul 30, 2026Analysis-
10-QJul 30, 2026Analysis
4Jul 28, 2026--
4Jul 28, 2026--
4Jul 28, 2026--
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
4Jun 3, 2026-
8-KJun 2, 2026Analysis
4May 28, 2026-

Related Health Care companies

All Health Care →

FLGT SEC filings: frequently asked questions

Are FLGT insiders buying or selling?

In the last 90 days, Fulgent Genetics, Inc. (FLGT) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $117,132 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold FLGT stock?

As of September 30, 2026, the largest Fulgent Genetics, Inc. (FLGT) holders among the 13F filers tracked by SignalX were BlackRock ($53.7 million), Two Sigma Investments ($20.5 million), Vanguard Capital Management LLC ($16.9 million), Ameriprise Financial ($14.7 million), Dimensional Fund Advisors ($14.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FLGT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Fulgent Genetics, Inc. (FLGT) reported revenue of $322.7 million (up 13.8% from FY2024) and a net loss of $60.5 million. The figures come from the XBRL data in the 10-K.

What did FLGT report in its latest 8-K?

Fulgent Genetics, Inc. (FLGT) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). 44,644-square-foot Needham facility supporting office, R&D, diagnostics, light manufacturing and warehousing.

What are the latest FLGT SEC filings?

Fulgent Genetics, Inc. (FLGT) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 28, 2026.

What is FLGT's SEC CIK number?

Fulgent Genetics, Inc. (FLGT)'s SEC Central Index Key (CIK) is 1674930. EDGAR lists every FLGT filing under that number.

Ask anything about FLGT

The research agent reads FLGT's filings, financials, insider trades and 13F holders, then answers with sources.